‚Äč

CME 1

 
09.00-12.15    HALL E
 

IWG    

  
IWG (Immunonephrology Working Group)
 

News in the diagnostics and treatment of glomerular disease

 

Critical review of renal biopsy

Indications for renal biopsy: when it is needed?
Loreto Gesualdo, Bari, Italy
Evidence based classification of renal pathology
Ian Roberts, Oxford, United Kingdom
Can biomarkers substitute renal biopsy in IgA nephropathy?
Yasar Caliskan, Istanbul, Turkey
What is the added value of renal biopsy and rebiopsy to clinical data in lupus
Gabriella Moroni, Pavia, Italy
What is the added value of renal biopsy to clinical data in vasculitis
Ingeborg M. Bajema, Leiden, The Netherlands

4 years after the KDIGO guidelines on glomerular diseases: when to update them?

Membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
IgA nephropathy
Jürgen Floege, Aachen, Germany
FSGS/minimal change disease
Rosanna Coppo, Turin, Italy
Lupus nephritis
David Jayne, Cambridge, United Kingdom
ANCA-associated vasculitis
Vladimir Tesar, Prague, Czech Republic

- See more at: http://www.era-edta2016.org/en-US/preliminary-scientific-programme#sthash.mCHnFyQj.dpuf

Part I
Critical review of renal biopsy

Chairs: Loreto Gesualdo, Bari, Italy
             Vladimir Tesar, Prague, Czech Republic

Indications for renal biopsy: when it is needed?
Loreto Gesualdo, Bari, Italy
Evidence based classification of renal pathology
Ian Roberts, Oxford, United Kingdom
Can biomarkers substitute renal biopsy in IgA nephropathy?
Yasar Caliskan, Istanbul, Turkey
What is the added value of renal biopsy and rebiopsy to clinical data in lupus
Gabriella Moroni, Pavia, Italy
What is the added value of renal biopsy to clinical data in vasculitis
Ingeborg M. Bajema, Leiden, The Netherlands


Part II
4 years after the KDIGO guidelines on glomerular diseases: when to update them?

Chairs: Rosanna Coppo, Turin, Italy
             Mårten Segelmark, Linköping, Sweden

Membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
IgA nephropathy
Jürgen Floege, Aachen, Germany
FSGS/minimal change disease
Rosanna Coppo, Turin, Italy
Lupus nephritis
David Jayne, Cambridge, United Kingdom
ANCA-associated vasculitis
Vladimir Tesar, Prague, Czech Republic

Critical review of renal biopsy

Indications for renal biopsy: when it is needed?
Loreto Gesualdo, Bari, Italy
Evidence based classification of renal pathology
Ian Roberts, Oxford, United Kingdom
Can biomarkers substitute renal biopsy in IgA nephropathy?
Yasar Caliskan, Istanbul, Turkey
What is the added value of renal biopsy and rebiopsy to clinical data in lupus
Gabriella Moroni, Pavia, Italy
What is the added value of renal biopsy to clinical data in vasculitis
Ingeborg M. Bajema, Leiden, The Netherlands

4 years after the KDIGO guidelines on glomerular diseases: when to update them?

Membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
IgA nephropathy
Jürgen Floege, Aachen, Germany
FSGS/minimal change disease
Rosanna Coppo, Turin, Italy
Lupus nephritis
David Jayne, Cambridge, United Kingdom
ANCA-associated vasculitis
Vladimir Tesar, Prague, Czech Republic

- See more at: http://www.era-edta2016.org/en-US/preliminary-scientific-programme#sthash.mCHnFyQj.dpuf

  

CME Courses on May 21, 2016 are reserved to regularly registered congress members and are included in the registration fee. In order to participate in the CME Courses, all regularly registered congress members must go to the session halls and have their badge scanned by the hostesses at the entrance (at participant’s own responsibility). Please note that the seat capacity of the conference rooms is limited, therefore participation in these courses will be on a “first come first served” basis.

  
back to the timetable

 

final programme "day by day" - may 21 - 24, 2016

today